KOD Kodiak Sciences Inc.
USHealthcareAs of 2026-07-10 16:00
Why KOD matters now
Kodiak Sciences Inc. (KOD) is a US stock in Healthcare. The latest InvestLog snapshot shows $41.31 with +3.07% on the session and $2.19B in market capitalization; recent performance reads 1-month +5.00% and YTD +29.26%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-58.2M, and EPS of $-0.94. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.7%.
The latest indexable market news headline is "Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $59.50; recent insider activity includes BORGESON JOHN A. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
19.94
P/S
0.00
EV/EBITDA
-9.45
DCF Value
$0.74
FCF Yield
-7.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-253.8%
ROA
-75.4%
ROIC
-87.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-58.2M | $-0.94 |
| Q4 2025 | $0.00 | $-56.7M | $-1.04 |
| FY 2025 | $0.00 | $-230.0M | $-4.32 |
| Q3 2025 | $0.00 | $-61.5M | $-1.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$63.75
Target (Median)
$59.50
Target Range
$56.00 - $80.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.21
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.